These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5543 related articles for article (PubMed ID: 18772890)
1. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Cancer Genome Atlas Research Network Nature; 2008 Oct; 455(7216):1061-8. PubMed ID: 18772890 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation. Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197 [TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme. Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831 [TBL] [Abstract][Full Text] [Related]
4. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme. Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102 [TBL] [Abstract][Full Text] [Related]
5. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882 [TBL] [Abstract][Full Text] [Related]
6. Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma. Shamsara J; Sharif S; Afsharnezhad S; Lotfi M; Raziee HR; Ghaffarzadegan K; Moradi A; Rahighi S; Behravan J Cancer Invest; 2009 Oct; 27(8):825-9. PubMed ID: 19544111 [TBL] [Abstract][Full Text] [Related]
7. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival. Shu C; Wang Q; Yan X; Wang J Cancer Med; 2018 Aug; 7(8):3704-3712. PubMed ID: 29984907 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Felsberg J; Rapp M; Loeser S; Fimmers R; Stummer W; Goeppert M; Steiger HJ; Friedensdorf B; Reifenberger G; Sabel MC Clin Cancer Res; 2009 Nov; 15(21):6683-93. PubMed ID: 19861461 [TBL] [Abstract][Full Text] [Related]
9. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients. Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189 [TBL] [Abstract][Full Text] [Related]
10. The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients. McDonald KL; Rapkins RW; Olivier J; Zhao L; Nozue K; Lu D; Tiwari S; Kuroiwa-Trzmielina J; Brewer J; Wheeler HR; Hitchins MP Eur J Cancer; 2013 Jan; 49(2):360-8. PubMed ID: 22975219 [TBL] [Abstract][Full Text] [Related]
11. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study. Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343 [TBL] [Abstract][Full Text] [Related]
12. Gliomatosis cerebri: no evidence for a separate brain tumor entity. Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382 [TBL] [Abstract][Full Text] [Related]
13. A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma. Wang W; Zhang L; Wang Z; Yang F; Wang H; Liang T; Wu F; Lan Q; Wang J; Zhao J Oncotarget; 2016 Oct; 7(43):69991-69999. PubMed ID: 27588397 [TBL] [Abstract][Full Text] [Related]
14. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398 [TBL] [Abstract][Full Text] [Related]
15. Molecular profiling in glioblastoma: prelude to personalized treatment. Mladkova N; Chakravarti A Curr Oncol Rep; 2009 Jan; 11(1):53-61. PubMed ID: 19080742 [TBL] [Abstract][Full Text] [Related]
16. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing. Xie H; Tubbs R; Yang B Int J Clin Exp Pathol; 2015; 8(1):636-42. PubMed ID: 25755756 [TBL] [Abstract][Full Text] [Related]
17. Whole-exome sequencing revealed mutational profiles of giant cell glioblastomas. Shi ZF; Li KK; Kwan JSH; Yang RR; Aibaidula A; Tang Q; Bao Y; Mao Y; Chen H; Ng HK Brain Pathol; 2019 Nov; 29(6):782-792. PubMed ID: 30861589 [TBL] [Abstract][Full Text] [Related]
18. Status of O⁶ -methylguanine-DNA methyltransferase [MGMT] gene promoter methylation among patients with glioblastomas from India. Nehru GA; Pai R; Samuel P; Chacko AG; Chacko G Neurol India; 2012; 60(5):481-6. PubMed ID: 23135024 [TBL] [Abstract][Full Text] [Related]
19. Learning MRI-based classification models for MGMT methylation status prediction in glioblastoma. Kanas VG; Zacharaki EI; Thomas GA; Zinn PO; Megalooikonomou V; Colen RR Comput Methods Programs Biomed; 2017 Mar; 140():249-257. PubMed ID: 28254081 [TBL] [Abstract][Full Text] [Related]